Management of Dry Eye Syndrome and Meibomian Gland Dysfunction (e.g., LipiFlow) 9.01.19
Excellus BlueCross BlueShield medical policy 9.01.19 considers eyelid thermal pulsation therapy to treat dry eye syndrome investigational, including LipiFlow, iLux System, TearCare and Tixel i. It also considers tear film imaging with the LipiView Ocular Surface Interferometer, used to evaluate dry eye syndrome and meibomian gland dysfunction, and near-infrared dual imaging with the LipiScan Dynamic Meibomian Imager, used to evaluate meibomian glands, investigational. The current effective date is December 18, 2025, and the December 18, 2025 annual review states that policy intent is unchanged.